FOLD
AMICUS THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$14.49
+0.00%Sep 21, 2026, 20:17 UTC
Travere Therapeutics appointed Bradley L. Campbell as President and Chief Executive Officer effective December 1, 2026.
Aug 12, 2026, 14:05 UTC
BioMarin Pharmaceutical announced plans to integrate Amicus Therapeutics as part of its rare-disease growth strategy, with a focus on faster deleveraging.
Source: